CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Clinical trial NCT05260957 · RECRUITING

Trial details

NCT number: NCT05260957
Sponsor: Lazaros Lekakis
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Non-Hodgkin Lymphoma Relapsed Non Hodgkin Lymphoma Aggressive Non-Hodgkin Lymphoma

Start date: 2022-12-14
Primary completion: 2026-12-31
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.